Navigation Links
Telik Announces Second Quarter 2009 Financial Results
Date:8/6/2009

PALO ALTO, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today reported a net loss of $5.7 million, or $0.11 per share, for the second quarter ended June 30, 2009, compared with a net loss of $13.6 million, or $0.26 per share, for the comparable period in 2008.

For the quarter ended June 30, 2009, total operating costs and expenses were $6.3 million, compared with $11.0 million in the 2008 second quarter. Operating expenses in the 2009 second quarter included stock-based compensation expense of approximately $0.5 million. Operating expenses were approximately 43% lower in the second quarter of 2009 compared with the same period in 2008, primarily due to lower headcount as a result of our restructuring in February 2009, reduced research, clinical trial and related expenses and lower stock compensation expense.

For the six months ended June 30, 2009, Telik reported a net loss of $13.4 million, or $0.25 per share, compared with a net loss of $23.4 million, or $0.44 per share, for the six months ended June 30, 2008. Total operating expenses for the first six months of 2009 were $14.0 million, compared with $21.6 million for the first six months of 2008. Operating expenses in the first six months of 2009 included approximately $1.3 million in stock-based compensation expense. The reduction in operating expenses of approximately 35% in the first six months of 2009 compared with the same period in 2008 was primarily due to lower headcount, reduced research and clinical trial expenses and lower stock-based compensation expense.

At June 30, 2009, Telik had $50.6 million in cash, cash equivalents and investments including restricted investments, compared to $63.5 million at December 31, 2008.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.

This press release contains "forward-looking" statements, including statements regarding the future development of TELINTRA and TELCYTA. These forward-looking statements are based upon Telik's current expectations. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements, including, among others, if clinical trials of TELINTRA or TELCYTA are delayed or unsuccessful, Telik's business would suffer, if Telik's competitors develop and market products that are more effective than its product candidates, or obtain marketing approval before Telik does, Telik's commercial opportunity will be reduced or eliminated, and if Telik does not obtain regulatory approval to market products in the U.S. and foreign countries, Telik will not be permitted to commercialize these product candidates. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the year ended December 31, 2008 and subsequent quarterly reports on Form 10-Q. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.

                                  Telik, Inc.
                           Statements of Operations
                   (In thousands, except per share amounts)
                                  (Unaudited)


                                       Three Months        Six Months
                                          Ended               Ended
                                         June 30,           June 30,
                                         --------           --------
                                       2009      2008      2009      2008
                                       ----      ----      ----      ----

    Operating costs and expenses:
      Research and development       $3,022    $8,236    $7,012    16,431
      General and
       administrative                 3,199     2,773     6,086     5,186
      Restructuring costs                83         -       951         -
                                         --       ---       ---       ---
        Total operating costs and
         expenses                     6,304    11,009    14,049    21,617
                                      -----    ------    ------    ------

    Loss from operations             (6,304)  (11,009)  (14,049)  (21,617)

    Interest and other income
     (expense), net                     623    (2,560)      663    (1,760)
                                        ---    ------       ---    ------
    Net loss                        $(5,681) $(13,569) $(13,386) $(23,377)
                                    =======  ========  ========  ========

    Basic and diluted net loss per
     share                           $(0.11)   $(0.26)   $(0.25)   $(0.44)
                                     ======    ======    ======    ======

    Weighted average shares used to
     calculate basic and diluted
      net loss per share             53,356    53,185    53,335    53,088
                                     ======    ======    ======    ======



                           Selected Balance Sheet Data
                                 (In thousands)
                                   (Unaudited)

                                                    June 30,   December 31,
                                                      2009         2008
                                                      ----         ----

    Cash, cash equivalents, investments
     and restricted  investments                     $50,560      $63,469

    Total assets                                     $57,143       75,413

    Stockholders' equity                             $50,278       62,372


'/>"/>
SOURCE Telik, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Telik Reports Preclinical Results at AACR Annual Meeting
2. Telik Implements Reorganization to Focus Resources Toward Drug Development Pipeline
3. Telik Announces New TRAP Drug Discovery Agreement
4. Telik Announces Financial Results for 2008 Third Quarter
5. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
6. Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
7. Telik Announces Receipt of Nasdaq Notice
8. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
9. ReceptorBio Announces Diabetes License Agreement With Telik
10. Telik Announces Financial Results For 2008 Second Quarter
11. Telik Announces 2008 Second Quarter Financial Release, Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader ... “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, ... providing practical tips, tools, and strategies for clinical researchers. , “The landscape of ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology:
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
Breaking Biology News(10 mins):